Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy

(2019) Alain Mina et al.   Cancers

Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON ‐1 Study

(2019) Ajit Suri et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study

(2018) Ajit Suri et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions

(2017) C A van der Weyden et al.   Blood Cancer Journal

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

(2016) R. Chen et al.   BLOOD

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management

(2015) Nabila Bennani-Baiti et al.   Expert Review of Hematology

Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma

(2014) Michinori Ogura et al.   CANCER SCIENCE

Brentuximab vedotin: An anti-CD30 antibody-drug conjugate

(2013) A. M. Bradley et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

(2008) K. J. Savage et al.   BLOOD

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

(2007) Yasuhiro Oki et al.   CANCER